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Abstract The coronavirus disease 2019 (COVID-19)
pandemic has led to preventive measures worldwide.
With the decline of infection rates, less stringent
restrictions for sports and exercise are being im-
plemented. COVID-19 is associated with significant
cardiovascular complications; however there are lim-
ited data on cardiovascular complications and long-
term outcomes in both competitive (elite) athletes
and highly active individuals. Based on different cat-
egories of disease severity (asymptomatic, regional/
systemic symptoms, hospitalisation, myocardial dam-
age, and/or myocarditis), in this point-of-view article
we offer the (sports) cardiologist or sports physician
in the Netherlands a practical guide to pre-partici-
pation screening, and diagnostic and management
strategies in all athletes >16 years of age after COVID-
19 infection.
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Introduction
With the implementation of less stringent coronavirus
disease 2019 (COVID-19) restrictions for sports and
exercise, healthcare professionals are faced with an in-
creasing number of athletes—both competitive (elite)
athletes and highly active individuals (>3h/week of
exercise)—seeking return-to-sports advice after recov-
ery from COVID-19. This is challenging, as evidence-
based recommendations for a return to sports after in-
fectious episodes are limited and heterogeneous. Dif-
ferent proposals regarding the resumption of sports
and exercise after COVID-19, e.g. from the Ameri-
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can College of Cardiology’s Sports and Exercise Car-
diology Council, have recently been published [1, 2].
Based on different categories of disease severity, in
this point-of-view article we offer the (sports) cardi-
ologist or sports physician in the Netherlands a prac-
tical guide to pre-participation screening (PPS), and
clinical management strategies in competitive (elite)
athletes and highly active individuals >16 years of age
after COVID-19.
General recommendations
Healthcare professionals should stay up-to-date and
adhere to the most recent national recommendations
from the National Institute for Public Health and En-
vironment [3]. Healthcare professionals directly in-
volved in athlete care should also stay up to date with
recommendations from the NOC*NSF [4] and other
relevant sports organisations. If national recommen-
dations do not cover specific circumstances, public
health considerations should always be taken into ac-
count and no unnecessary risks are acceptable that
could lead to further spread of severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2).
Cardiac considerations for COVID-19
Studies on critically ill, hospitalised patients have
shown that infection with SARS-CoV-2 is associated
with several cardiovascular complications [5–8]. The
mechanism of cardiac injury from COVID-19 has not
yet been fully elucidated, but is likely multifactorial [9,
10]. For an overview of all described complications,
see Tab. 1. The background of the cardiovascular
complications is extensively discussed elsewhere in
this issue of the Netherlands Heart Journal.
As the precise mechanisms and long-term conse-
quences of the interaction between SARS-CoV-2 and
different (in particular cardiac) tissues are unknown,
it is consequently unknown whether patients with (re-
gional/systemic) symptoms are prone to cardiovascu-
lar sequelae after COVID-19 and what the influence of
sports and exercise is on these potential sequelae.
Specific considerations for athletes after COVID-
19
Some considerations should be taken into account
when assessing the scope of COVID-19 and poten-
tial cardiovascular complications in athletes. First,
based on currently available reports, myocarditis lead-
ing to congestive heart failure and arrhythmias is di-
agnosed infrequently in patients with COVID-19, and
no cases have been published describing elite ath-
letes with SARS-CoV-2 myocarditis [10–14]. However,
all-cause myocarditis is a significant cause of sudden
cardiac death and sudden cardiac arrest (SCD/SCA)
in young athletes [15], with case series reporting my-
ocarditis as a potential cause of SCD/SCA in up to 8%
Table 1 Cardiac considerations in COVID-19
Mechanism of cardiovascular injury
Hypoxaemia
Myocardial infarction




[16]. Second, athletes are not a high-risk group for
a severe course of COVID-19. Athletes in general and
elite athletes in particular are younger, which is asso-
ciated with a milder course of COVID-19 [17]. They
also have fewer cardiac comorbidities, and a lower
prevalence of obesity, diabetes mellitus and hyper-
tension. Third, moderate exercise training reduces
the risk, duration, and severity of viral infections in
general, and regular exercise has positive effects on
pulmonary function [18].
However, severe cases of COVID-19 requiring hos-
pitalisation have been described in younger individ-
uals without comorbidities [19]. Furthermore, older
athletes or athletes with cardiovascular comorbidities
who are at risk for a severe course of COVID-19 will
wish to resume sports and exercise. The optimal ap-
proach to sports resumption in these individuals is
unclear, as data are lacking on cardiovascular com-
plications and cardiac injury in patients with mild
or asymptomatic COVID-19. Considering the possi-
ble severe consequences of cardiac complications of
COVID-19 in athletes, we recommend that an early
diagnostic evaluation should take place in individuals
aiming to return to sports after recovery from COVID-
19.
Active COVID-19
Athletes with active COVID-19 should cease all sports
activities and undergo self-isolation at home for the
entire symptomatic period [4]. While COVID-19-spe-
cific data are lacking, waiting 7–14 days after resolu-
tion of all symptoms, and a minimum of 10 days after
onset of symptoms before resuming exercise seems
reasonable. After that, gradual resumption of exercise
and sports can be considered, based on the severity
and duration of symptoms and after stratification if
PPS is indicated.
After recovery from COVID-19
We stratify athletes that have recovered from the initial
SARS-CoV-2 infection as:
 asymptomatic or local symptoms (non-hospitalised)
 regional or systemic symptoms (non-hospitalised)
 hospitalised and no myocardial injury
 hospitalised and myocardial injury
 myocarditis
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Fig. 1 Flowchart for stratification of athletes after COVID-
19 for pre-participation screening, diagnostic and therapeu-
tic considerations. (ECG electrocardiogram, CMR cardio-
vascular magnetic resonance, CVD cardiovascular disease.
aAsymptomatic/non-systemic symptoms verified by critical
evaluation of signs and symptoms by general practitioner or
other qualified healthcare professional. bSee Tab. 2 for an out-
line of local, regional and systemic symptoms. cRed flags sug-
gestive of cardiac pathology in the 12-lead ECG are outlined
in Tab. 3)
Fig. 1 shows a flowchart to assist clinicians in stratifi-
cation, and suggests PPS, diagnostic and therapeutic
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Difficulty in breathing Anosmia/ageusia
Runny nose Rapid breathing/
shortness of breath
Myalgia/arthralgia
Sinus pressure Chest pain Skin manifestations (ery-
thema, urticaria)







Asymptomatic or local symptoms (non-hospitalised)
PPS of athletes after asymptomatic infection or lo-
cal symptoms (Tab. 2) of COVID-19 is not indicated
if a critical evaluation of signs and symptoms (by gen-
eral practitioners or other qualified healthcare profes-
sionals) is negative and shows a complete recovery.
The chance of cardiac sequelae is probably negligible
in such individuals. Feasibility, cost considerations
and burdening of local health care systems should be
considered if extending the indication for PPS to low-
risk individuals. However, a PPS and consultation by
a (sports) cardiologist may be considered for specific
groups. These groups include, but are not limited
to, athletes with pre-existent cardiovascular pathol-
ogy, elite athletes and athletes with impaired recovery
of exercise capacity.
Regional or systemic symptoms (non-hospitalised)
PPS of patients after COVID-19 with regional or sys-
temic symptoms (see Tab. 2 for an outline of regional
and/or systemic symptoms) not requiring hospitalisa-
tion should be strongly considered. PPS includes criti-
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Table 3 Red flags in ECG suggestive of cardiovascular
complications
Tachycardia at rest






Left bundle branch blocks
Low QRS voltage (suggestive of pericardial effusion or myocardial oedema)
Signs of right ventricular pressure overload
cal evaluation of symptoms, physical examination and
a 12-lead electrocardiogram (ECG). Red flags sugges-
tive of cardiac pathology in the 12-lead ECG are out-
lined in Tab. 3. We emphasise that a 12-lead ECG is not
the gold standard for the detection of myocarditis and
other cardiovascular complication, and that a normal
ECG does not rule out myocarditis in the presence
of signs and symptoms suggestive of myocarditis [16,
20]. If needed, a (sport) cardiologist with experience
in reading athletes’ ECGs should be consulted when
differentiating between ECG changes due to cardiac
adaptation to sports and exercise and ECG abnormal-
ities suggestive of cardiac pathology [21]. Using car-
diac biomarkers to screen for myocarditis has been
suggested [1]. However, we advise caution when us-
ing such a screening strategy. First, most athletes do
not have previously documented baseline measure-
ments and, second, elevated biomarker levels have
been demonstrated after exercise in various athletes
across different sports, without clear-cut clinical im-
plications [22].
If the patient has completely recovered and is
asymptomatic, and the 12-lead ECG is normal, grad-
ual resumption of sports seems warranted. In the case
of complaints or ECG abnormalities suggestive of car-
diovascular complications, patients should be referred
to a (sports) cardiologist for further evaluation. This
evaluation should include at least an exercise test and
an echocardiogram, but further diagnostic tests such
as Holter monitoring or cardiac magnetic resonance
imaging (CMR) can be considered. In the case of per-
sistent cardiopulmonary complaints without a cardiac
substrate, ruling out a pulmonary embolism should
be considered.
Hospitalised and no myocardial injury
Patients with severe COVID-19 requiring hospital or
intensive care admission, without signs of myocardial
damage or cardiovascular complications, should be
advised to first complete a comprehensive, multidis-
ciplinary rehabilitation programme before resuming
sports and exercise [23]. After completing rehabilita-
tion, PPS and an exercise test should be performed
before the patient resumes sporting activities.
Hospitalised and myocardial injury
In the case of myocardial damage and/or newly di-
agnosed cardiovascular complications during hospi-
tal admission, the primary focus should be to treat
the relevant pathology according to current cardio-
vascular guidelines [20, 24–26]. After discharge, com-
prehensive rehabilitation should be prioritised with
monitoring for late cardiac complications. A return to
sports should take place only after a complete cardio-
vascular evaluation.
Myocarditis
If SARS-CoV-2 myocarditis is diagnosed, comprehen-
sive clinical evaluation should take place, including
CMR. In patients with myocarditis we advise intensive
monitoring after discharge, and a sports restriction for
at least 3–6 months, based on general myocarditis rec-
ommendations [20]. A return to sports should be eval-
uated by a multidisciplinary, expert team, and include
input from sports cardiology and sports medicine.
Limitations
Due to the lack of data on athletes with COVID-19,
all recommendations in this point-of-view article are
based on expert opinion and expert consensus. With
the explosive growth of publications on COVID-19,
this statement should be interpreted only in the con-
text of the most recent peer-reviewed publications
and (inter)national society recommendations. A reg-
istry of COVID-19 cases among athletes and highly
active individuals, including follow-up, is needed to
provide an evidence-based approach for a return to
sports after recovery from SARS-CoV-2 infection.
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